IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.

doi:10.1677/JME-08-0051

CSMUIR > Medical College > School of Medicine > Journal paper > Item 310902500/11599

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/11599

Title:	IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.
Authors:	Chang, MH Kuo, WW Chen, RJ Lu, MC Tsai, FJ Kuo, WH Chen, LY Wu, WJ Huang, CY Chu, CH
Contributors:	中山醫學大學
Date:	2008
Issue Date:	2015-07-23T09:48:32Z (UTC)
ISSN:	0952-5041
Abstract:	The IGF-II/mannose 6-phosphate receptor (IGF2R) function in extracellular matrix (ECM) remodeling is known to occur as a result of transforming growth factor-beta (TGF-beta) activation and plasmin in the proteolytic cleavage level caused by the interaction between latent TGF-beta and urokinase plasminogen activator receptor (uPAR) respectively. In one of our previous studies, we found IGF-II and IGF2R dose-dependently correlated with the progression of pathological hypertrophy remodeling following complete abdominal aorta ligation. However, how this IGF2R signaling pathway responds specifically to IGF-II and regulates the myocardial ECM remodeling process is unclear. We found that IGF2R was aberrantly expressed in myocardial infarction scars. The matrix metalloproteinase-9 (MMP-9) zymographic activity was elevated in H9c2 cardiomyoblast cells treated with IGF-II, but not IGF-I. Treatment with Leu27IGF-II, an IGF2R specifically binding IGF-II analog, resulted in significant time-dependent increases in the MMP-9, tissue-type plasminogen activator (tPA), and urokinase plasminogen activator (uPA); and a reduction in the tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) protein expression. Furthermore, IGF2R expression inhibition by siRNA blocked the IGF-II-induced MMP-9 activity. We hypothesize that after IGF-II is bound with IGF2R, the resulting signal disrupts the balance in the MMP-9/TIMP-2 expression level and increases plasminogen activator (PAs) expression involved in the development of myocardial remodeling. If so, IGF2R signaling inhibition may have potential use in the development of therapies preventing heart fibrosis progression.
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/11599 http://dx.doi.org/10.1677/JME-08-0051
Relation:	J Mol Endocrinol. 2008 Aug;41(2):65-74.
Appears in Collections:	[School of Medicine] Journal paper

Files in This Item:

File	Description	Size	Format
index.html	期刊論文	0Kb	HTML	264	View/Open

View Licence

Loading...